Guggenheim maintains Entrada Therapeutics at Buy, lowers price target to $13 from $17
Guggenheim has reiterated its "Buy" rating for Entrada Therapeutics but has adjusted its price target down to $13 from $17, a 23.5% reduction. Despite the lower target, this still implies a significant upside of 162.1% from the stock's closing price of $4.96 on November 17. Investors can find more detailed price target data, ratings, and analyst recommendations for Entrada Therapeutics on TradingView's Forecasts tab and News Flow.
The Technical Signals Behind (TRDA) That Institutions Follow
This article from Stock Traders Daily analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models to generate trading strategies. It highlights near-term weak sentiment, mid-term strength, and a broader long-term weak bias, identifying key support and resistance levels. The report also details specific long and short position trading, momentum breakout, and risk hedging strategies for TRDA.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics announced that an independent safety data monitoring committee has recommended initiating Cohort 3 of its ELEVATE-45-201 study at an increased dose of 15 mg/kg for ENTR-601-45 in Duchenne muscular dystrophy (DMD). This recommendation follows a review of data from eight participants in Cohort 2, which was dosed at 10 mg/kg. While this is a progression in an early-stage program, efficacy data for Cohort 2 is expected in the first half of 2027, with Cohort 3 data to follow.
$193 million in cash and investments is expected to fund Entrada's operations into Q4 2027.
Entrada Therapeutics (Nasdaq: TRDA) reported a narrowed net loss of $39.7 million for Q3 2026, down from $44.1 million a year prior, while its nine-month net loss increased to $122.2 million. The company's cash, cash equivalents, and marketable securities totaled $193.0 million as of September 30, 2026, and are projected to fund operations into Q4 2027. Entrada also provided updates on its Duchenne muscular dystrophy clinical trials, with several data readouts anticipated through the first half of 2027, and announced an orphan drug designation for ENTR-601-45.
Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c
Entrada Therapeutics, Inc. (TRDA) reported a Q3 EPS of ($0.94), surpassing the analyst estimate of ($1.01) by $0.07. However, the company's revenue for the quarter came in at $900 thousand, which was below the consensus estimate of $2.11 million. The stock price was noted at $4.63, down 8.5% on the day.
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) reported a narrower Q3 loss of $0.94 per share, surpassing the Zacks Consensus Estimate of a $0.98 loss, but missed revenue estimates with $0.91 million against an expected $1.61 million. The company's shares have significantly underperformed the S&P 500 year-to-date. Investors are advised to watch for management's commentary on the earnings call and future estimate revisions, as the stock currently holds a Zacks Rank #3 (Hold).
Entrada Therapeutics Reports Q3 2026 Results, $193 Million in Cash
Entrada Therapeutics announced its Q3 2026 financial results, reporting $0.9 million in collaboration revenue and a net loss of $39.7 million. The company ended the quarter with $193.0 million in cash, cash equivalents, and marketable securities, projected to fund operations into Q4 2027. Entrada also provided updates on its Duchenne muscular dystrophy programs, including expected data readouts and orphan drug designation for ENTR-601-45.
Revenue fell to $2.7M over nine months as Entrada Therapeutics (TRDA) widened its loss.
Entrada Therapeutics (TRDA) reported a widened net loss of $122.2 million for the first nine months of 2026, compared to $104.6 million in the same period of 2025, with collaboration revenue falling to $2.7 million from $24.1 million. The company's third-quarter net loss, however, narrowed to $39.7 million from $44.1 million year-over-year. Entrada also faces substantial doubt about its ability to continue as a going concern within 12 months, despite having $193.0 million in cash, cash equivalents, and marketable securities, which is estimated to fund operations into Q4 2027.
Entrada Therapeutics, Inc. (TRDA) Seasonal returns chart
This article provides a seasonal returns chart for Entrada Therapeutics, Inc. (TRDA), displaying the average monthly price return from 2021 to 2026. The data is presented on Yahoo Finance, showing the stock's performance trends over different periods.
Entrada Therapeutics, Inc. Estimates – NASDAQ:TRDA
This page provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) financial estimates, including income statement, balance sheet, cash flow, and valuation metrics. It allows users to explore reported financial data and analyst estimates, compare actual results with average, high, and low estimates, and visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics (Nasdaq: TRDA) has appointed Linea Aspesi as its new Chief People Officer. Ms. Aspesi brings over twenty years of experience in organizational leadership and culture transformation within biopharmaceutical and technology companies, with a focus on scaling organizations through various stages of growth. Her role will be crucial in building an industry-leading culture as Entrada advances its neuromuscular programs and genetic medicine pipeline.
Entrada Therapeutics names Linea Aspesi as chief people officer By Investing.com
Entrada Therapeutics (NASDAQ:TRDA) has announced the appointment of Linea Aspesi as Chief People Officer. Aspesi brings over 20 years of experience in organizational leadership within biopharmaceutical and technology companies, with a focus on scaling organizations through various growth stages. She previously held a similar role at KalVista Pharmaceuticals and has served in executive HR positions at several other life science companies.
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics has appointed Linea Aspesi as its new Chief People Officer. Aspesi brings over twenty years of experience in organizational leadership, focusing on scaling biopharmaceutical and technology companies and developing high-performing teams. Her appointment comes as Entrada is in a "catalyst-rich period" with its neuromuscular programs, and she will be instrumental in building the company's culture and supporting its growth.
Entrada Therapeutics names Linea Aspesi as chief people officer
Entrada Therapeutics, Inc. (NASDAQ:TRDA) has announced the appointment of Linea Aspesi as its new Chief People Officer. Aspesi brings over two decades of experience in organizational leadership within the biopharmaceutical and technology sectors, with a focus on scaling companies through growth and implementing culture strategies. Her previous roles include Chief People Officer at KalVista Pharmaceuticals and executive HR positions at other life science firms.
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics has announced the appointment of Linea Aspesi as its new Chief People Officer. Aspesi brings over twenty years of experience in culture transformation and scaling organizations in the biopharmaceutical and technology sectors. Her expertise will be crucial as Entrada enters a catalyst-rich period with its neuromuscular programs and continues to build a high-performing team to advance its pipeline.
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics (Nasdaq: TRDA) has appointed Linea Aspesi as its new Chief People Officer. Ms. Aspesi brings over twenty years of experience in organizational leadership and culture transformation in the biopharmaceutical and technology sectors. In her new role, she will focus on scaling Entrada's people and organization during a period of significant growth, particularly with its neuromuscular programs.
Entrada Therapeutics posts positive Phase 1/2 Cohort 1 topline data for ENTR-601-45, safety OK
Entrada Therapeutics (TRDA) announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45, reporting favorable safety and tolerability at 5 mg/kg IV. The study showed a mean increase of 0.10% in dystrophin and 0.15% in exon skipping in treated participants. The company is on track to report Cohort 2 data in H1 2027 and subsequently Cohort 3 data.
Entrada Therapeutics Announces Positive Results From the First Cohort of Participants With Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announced positive results from the first cohort of participants with Duchenne Muscular Dystrophy (DMD) in its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45. The study showed encouraging safety and tolerability, alongside a significant increase in dystrophin expression in muscle biopsies, indicating the potential therapeutic benefit of the treatment. These findings support the continued development of ENTR-601-45 as a novel therapy for DMD.
Entrada receives clearance to test highest dose in DMD trial
Entrada Therapeutics Inc. (NASDAQ:TRDA) has received clearance from an independent Data Monitoring Committee to advance to the highest planned dose level (18 mg/kg) in its ongoing Phase 1/2 clinical trial for ENTR-601-44, a treatment for Duchenne muscular dystrophy. This recommendation follows a review of safety and pharmacokinetic data from eight participants in Cohort 2. The company expects to release data from Cohort 1 participants by year-end 2026 and Cohort 2 data in the first quarter of 2027.
Entrada Therapeutics Reports Phase 1/2 Data for ENTR-601-45 in DMD Exon 45 Skipping
Entrada Therapeutics announced positive results from the first cohort of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45, a treatment for Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping. The study found favorable safety and tolerability, with a mean increase of 0.10% in dystrophin production and 0.15% in exon skipping, though no functional benefit was observed in this initial cohort. The EEV platform aims to improve the delivery of phosphorodiamidate morpholino oligomers to muscle tissue, a crucial aspect for DMD treatment.
What's Going On With Entrada Therapeutics Stock Wednesday?
Entrada Therapeutics (NASDAQ: TRDA) shares dropped over 15% after the company released topline results from the first cohort of its Phase 1/2 ELEVATE-45-201 clinical trial for ENTR-601-45, a treatment for Duchenne muscular dystrophy. While functional benefits were not expected or observed at this early stage due to low dosing, the trial demonstrated a highly favorable safety profile, and participants showed an increase in dystrophin production and exon skipping. Future trial phases will explore higher doses and longer durations to assess functional impact.
(TRDA) Movement Within Algorithmic Entry Frameworks
Entrada Therapeutics Inc. (NASDAQ: TRDA) is exhibiting weak sentiment across all time horizons, supporting a short bias according to AI models. The analysis identifies a significant 266.0:1 risk-reward setup targeting a 62.0% gain versus 0.2% risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—have been generated, each with specific entry, target, and stop-loss levels.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended initiating Cohort 3 of its ELEVATE-44-201 study at the top dose of 18 mg/kg for ENTR-601-44, a potential treatment for Duchenne muscular dystrophy. This advancement follows a review of safety and PK data from Cohort 2, with data from Cohort 1 expected by year-end 2026 and Cohort 2 in Q1 2027. The higher dose aims to increase exposure, dystrophin production, and functional benefit.
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45 in Duchenne Muscular Dystrophy (DMD) patients. The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with a 0.10% mean increase in dystrophin production and 0.15% mean increase in exon skipping observed. The company expects greater dystrophin production and functional benefits in subsequent higher-dose cohorts, with Cohort 2 data anticipated in early 2027.
A Duchenne treatment study may test its highest dose yet. One group's data are expected by year-end.
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 3 at the top dose of 18 mg/kg in its Phase 1/2 ELEVATE-44-201 study for Duchenne muscular dystrophy. This follows successful enrollment in Cohort 2 and aims to deepen the understanding of the drug's safety, pharmacokinetic, and pharmacodynamic profile. Entrada expects to release Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027.
An experimental Duchenne treatment showed a muscle-protein increase and could be given about nine times a year.
Entrada Therapeutics announced positive topline data from the first cohort of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45, a Duchenne muscular dystrophy treatment. The study showed the drug met primary safety objectives and resulted in a 0.10% mean increase in dystrophin production, a muscle-supporting protein, in treated participants. The company highlights a potential dosing schedule of approximately nine administrations per year, a significant improvement over weekly infusions for current therapies, and expects higher doses in future cohorts to provide functional benefits.
Entrada Says First Cohort of ENTR-601-45 Phase 1/2 Trial Shows 'Positive' Safety Results in Duchenne Muscular Dystrophy
Entrada Therapeutics (TRDA) announced positive safety results for the first cohort of its ENTR-601-45 phase 1/2 trial for Duchenne Muscular Dystrophy. This news was released on Wednesday, October 14, 2026. The full article content requires a premium subscription.
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45 in Duchenne Muscular Dystrophy (DMD) patients. The study met its primary objectives of favorable safety and tolerability at a 5 mg/kg dose, and showed a 0.10% mean increase in dystrophin production. Enrollment for Cohort 2 is complete, and the company expects to report data for the higher 10 mg/kg dose in the first half of 2027, with the potential for increased dystrophin production and functional benefits in future cohorts.
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for Duchenne Muscular Dystrophy (DMD). The study met its primary objectives for safety and tolerability at a 5 mg/kg dose, and showed a mean increase of 0.10% in dystrophin production and 0.15% in exon skipping. The company expects significantly higher dystrophin production and functional benefits in subsequent cohorts at increased doses, maintaining a convenient Q6W dosing schedule.
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully
Entrada Therapeutics (NASDAQ:TRDA) is an unprofitable biotech company with a cash burn of US$134m in the last year, giving it a cash runway of about 20 months. Its operating revenue decreased by 94% year-on-year, and its cash burn increased by 6.2%. With a market capitalization of US$275m, the cash burn represents 49% of its market value, suggesting a potentially painful capital raise if needed.
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares
Entrada Therapeutics CEO Dipal Doshi reported a mandatory sell-to-cover disposition of 8,724 shares of TRDA common stock on September 2, 2026, to satisfy tax withholding obligations. This was not a discretionary sale. Following this transaction, Doshi directly holds 517,290 shares of the company, with the disposed shares sold at a weighted average price of $7.1439.
MPM BioVentures 2014, L.P. Offloads 259,837 Shares of Entrada Therapeutics (NASDAQ: TRDA) at $7.11-$7.41 Each
MPM BioVentures 2014, L.P. sold 259,837 shares of Entrada Therapeutics (NASDAQ: TRDA) between September 4 and September 9, 2026, at prices ranging from $7.11 to $7.41 per share. Following these transactions, the insider's reported ownership stands at 3,885,115 shares. These sales were executed as open-market transactions, and MPM BioVentures 2018, L.P. is also noted as an insider.
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Entrada Therapeutics has announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to Parent Project Muscular Dystrophy (PPMD) in the U.S. and Duchenne Parent Project Netherlands. These grants support projects aimed at bridging healthcare disparities within the global Duchenne muscular dystrophy community. The initiatives will focus on improving access to specialized care for underserved populations, particularly adults and those in rural areas, and promoting autonomy and social participation for individuals transitioning into adulthood.
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock
MPM BioVentures 2014, L.P., a 10% owner of Entrada Therapeutics (NASDAQ:TRDA), sold approximately $1.91 million worth of common stock in early September 2026. The sales occurred over three trading days with weighted average prices between $7.11 and $7.41 per share, amidst operational challenges for Entrada, including rapid cash burn and an anticipated revenue decline. Despite the sales, InvestingPro analysis suggests the shares are undervalued with a Fair Value of $7.91.
MPM funds sell 259,837 Entrada Therapeutics (TRDA) shares over 3 days
Investment funds affiliated with MPM BioVentures, identified as ten percent owners of Entrada Therapeutics, Inc. (TRDA), indirectly sold a total of 259,837 shares of Common Stock over three days in September 2026. The sales occurred at weighted average prices ranging from approximately $7.01 to $7.70 per share. Following these transactions, the MPM entities reported remaining holdings across various partnerships and LLCs.
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com
MPM BioVentures 2018, a significant shareholder and director of Entrada Therapeutics, recently sold approximately $1.91 million worth of the company's common stock across three separate transactions in early September 2026. The sales occurred while TRDA shares were trading around $7.11, following a 31% year-to-date decline but a 36% gain over the past year. Following these transactions, MPM BioVentures 2018 and its affiliated entities indirectly retain ownership of over 3.8 million shares.
MPM funds sell Entrada (TRDA) shares, still hold stakes over 1.7M each
Funds affiliated with MPM BioVentures, which are ten percent owners of Entrada Therapeutics (TRDA), recently sold a total of 259,837 shares in several open-market transactions between September 4 and September 9, 2026. Despite these sales, the funds retain substantial holdings, with MPM BioVentures 2014, L.P. holding 1,764,167 shares and MPM BioVentures 2018, L.P. holding 1,810,592 shares. The sales occurred at weighted average prices ranging from $7.11 to $7.41 per share, and no Rule 10b5-1 trading plan was reported.
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares
MPM BioVentures 2018, L.P. and its affiliates, a significant owner of Entrada Therapeutics Inc. (NASDAQ:TRDA), recently sold approximately $1.91 million worth of company shares in early September 2026. The sales occurred across three transactions with weighted average prices ranging from $7.11 to $7.41 per share, while Entrada's stock trades at $7.11, down 31% year-to-date but up 36% over the past year. Despite the sales, InvestingPro analysts suggest Entrada is undervalued, with price targets between $11 and $25.
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com
MPM BioVentures, a 10% owner and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold common stock worth $617,378 between September 1 and September 3, 2026. A total of 86,482 shares were sold at weighted average prices ranging from $7.06 to $7.19. Following these transactions, MPM BioVentures and its affiliates still beneficially own 4,144,952 shares of Entrada Therapeutics.
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics
MPM BioVentures, a 10% owner of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold 86,482 shares of common stock for a total of $617,378 between September 1 and September 3, 2026. The sales were made at weighted average prices ranging from $7.06 to $7.19. Following these transactions, MPM BioVentures and its affiliates beneficially own 4,144,952 shares of Entrada Therapeutics.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics announced the grant of inducement stock options to five new employees. These grants, totaling 74,400 shares of common stock, were made outside the company's 2021 Equity Incentive Plan but conform to Nasdaq Listing Rule 5635(c)(4). The options vest over four years, subject to continued employment, and have an exercise price equal to the closing price on the grant date.
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days
MPM-affiliated entities, identified as ten percent owners of Entrada Therapeutics (NASDAQ: TRDA), sold a total of 86,482 common shares over three days in early September 2026. The sales occurred between September 1-3, 2026, with weighted average prices ranging from approximately $7.06 to $7.19 per share. These transactions were indirect sales across several MPM limited partnerships and LLCs, and no Rule 10b5-1 trading plan was reported.
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock
MPM BioVentures 2014 L.P., a significant owner of Entrada Therapeutics (TRDA), sold 86,914 shares totaling $615,777 in late August 2026, despite analysts maintaining a "strong buy" consensus for the stock. The sales occurred across three transactions as the stock traded at $7.05, down 31% year-to-date, though InvestingPro analysis suggests it remains undervalued. Concurrently, Entrada Therapeutics received approval to proceed with a higher dose in its Duchenne Muscular Dystrophy study, marking a positive development in its research efforts.
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com
MPM BioVentures 2018, L.P., a major shareholder in Entrada Therapeutics (NASDAQ:TRDA), sold $615,777 worth of common stock between August 27 and August 31, 2026, at prices ranging from $6.99 to $7.2 per share. Following these transactions, the entity and its affiliates indirectly hold 4,231,434 shares. Despite the sales, analysts view the stock as undervalued, with price targets between $11 and $25, and the company recently received clearance to escalate the dose in its Duchenne muscular dystrophy drug trial.
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
MPM BioVentures 2018, a significant shareholder in Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $461,545 over three days, with prices ranging from $7.06 to $7.54. These sales occurred as the stock experienced an 8% decline for the week, despite InvestingPro analysis suggesting it is undervalued with a fair value of $7.95. Concurrently, Entrada Therapeutics received approval to increase the dosage in its Duchenne muscular dystrophy study, marking a positive clinical development.
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com
MPM BioVentures 2014, L.P., a 10% owner and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold a total of $461,545 worth of common stock over three days in late August 2026. The sales occurred at weighted average prices between $7.06 and $7.54 per share. Despite these sales, analysts maintain a consensus Buy rating on Entrada Therapeutics, with price targets ranging from $11 to $25.
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock
MPM BioVentures 2014, L.P., a significant shareholder and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold $461,545 worth of common stock in late August 2026 across three separate transactions. The sales occurred at weighted average prices between $7.06 and $7.54 per share, leaving MPM BioVentures 2014, L.P. with 4,318,348 shares indirectly. The biotech company, with a market cap of $252 million, faces financial challenges despite analysts maintaining a consensus "Buy" rating.
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) shares recently surged by 8.9%, closing at $15.79, driven by investor optimism regarding its product pipeline and upcoming clinical milestones for RNA-based therapies. The company is advancing several candidates for neuromuscular diseases, with key data readouts and clinical milestones anticipated in 2026. Despite a projected quarterly loss and revenue decline, the stock currently holds a Zacks Rank #3 (Hold).
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50 and is ranked 109th in the Biotechnology & Medical Research industry. Analysts project a target price of $16.50 for TRDA, with an expected revenue of $5.26M for the next quarter. Most analysts recommend a "Buy" for Entrada Therapeutics Inc, though investors should conduct their own research.
HC Wainwright Analysts Lower Earnings Estimates for TRDA
HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and revenue of $0.90 million versus a $2.32 million consensus. Despite high institutional ownership, analyst sentiment remains mixed with a consensus "Hold" rating and a target price of $17.50, significantly higher than its recent trading price of $7.04.